What is the 13F Pro Quality Score for RCUS?

13F Pro ranks Arcus Biosciences, Inc. (RCUS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RCUS's current score at https://13fpro.ai/company/RCUS (free sign-up required for the full ranking).

Which hedge funds own the most RCUS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RCUS include GILEAD SCIENCES,, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/RCUS as soon as new 13F filings post.

Where does 13F Pro source RCUS data?

All Arcus Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Arcus Biosciences, Inc. files with the SEC under CIK 1724521. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RCUS in?

Arcus Biosciences, Inc. (RCUS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RCUS research updated on 13F Pro?

RCUS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arcus Biosciences, Inc.(RCUS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1724521 RCUS stock profile & AI dashboard →

13F Pro Quality Score

8.5/100

Rank #2,927 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

1.9/100

Profitability

3.7/100

Balance Sheet

4.1/100

Earnings Quality

9.4/100

Free Cash Flow

3.0/100

Institutional Flow

50.8/100

Revenue Scale

17.8/100

Dilution Risk

7.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RCUS Scores 9/100

exact factor attribution · 2026-09-11

RCUS's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+0.0 pts

51th pct

Shareholder dilution

-2.1 pts

7th pct

Earnings growth

-2.3 pts

4th pct

Earnings quality

-4.1 pts

9th pct

Capital efficiency

-4.6 pts

4th pct

Scale

-4.8 pts

18th pct

Profitability

-6.9 pts

4th pct

Free cash flow

-7.0 pts

3th pct

Revenue growth

-9.6 pts

2th pct

Latest change (2026-08-05): 12 → 6 · ↓ Revenue growth 32→3

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RCUS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Arcus Biosciences, Inc. (RCUS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RCUS at 8.5/100 on a 32-signal composite quality model, placing it at rank #2,927 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.9) and free cash flow (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcus Biosciences, Inc. reports quarterly revenue of $41.0M, net income of $-91.0M, free cash flow of $-119.0M. Top institutional holders of RCUS by reported 13-F value include GILEAD SCIENCES, BlackRock, STATE STREET, based on the most recent SEC filings. RCUS trades on the NYSE exchange and files with the SEC under CIK 1724521. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcus Biosciences, Inc. directly from SEC EDGAR. Arcus Biosciences, Inc.'s 13F Pro composite quality score has ranged between 6 and 47 since 2021, currently 8.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Arcus Biosciences, Inc.

Quirks, history, and lore behind RCUS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on the NYSE · headquartered in Hayward, California · focused on oncology and immunology.
2
The Numbers
A pre-profitability biotech with a market cap in the low hundreds of millions, it burns cash funding trials but has secured significant collaboration revenue from a major pharmaceutical partner.
3
The History
Founded in 2015 by veterans of leading cancer drug programs, it went public in 2018 and quickly attracted partnership interest from a top-10 global pharma.
4
The Secret
Its strategy centers on combination immunotherapy — stacking drugs that block multiple immune checkpoints at once, betting that no single pathway is enough to defeat cancer.
5
The Lore
Gilead Sciences struck a major collaboration deal with the company, paying a hefty upfront sum — a vote of confidence that put this small biotech on the oncology map.
6
The Giveaway
Its ticker spells out a curve, its name evokes a bow in the sky, and its pipeline targets CD73, TIGIT, and adenosine pathways — the immune checkpoint alphabet only serious oncology investors know by heart.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$41.0M

Net Income

Q2 2026

$-91.0M

Free Cash Flow

Q2 2026

$-119.0M

ROIC

Q2 2026

-68.0%

D/E Ratio

Q2 2026

0.22

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-4.3% YoY

$247.0MFY 2025

FY22 $112.0MFY23 $117.0MFY24 $258.0MFY25 $247.0M

Net Income

-24.7% YoY

$-353.0MFY 2025

FY22 $-267.0MFY23 $-307.0MFY24 $-283.0MFY25 $-353.0M

Operating Income

-17.0% YoY

$-386.0MFY 2025

FY22 $-280.0MFY23 $-340.0MFY24 $-330.0MFY25 $-386.0M

EPS (Diluted)

-4.8% YoY

$-3.29FY 2025

FY22 $-3.71FY23 $-4.15FY24 $-3.14FY25 $-3.29

Total Assets

-1.0% YoY

$1.14BFY 2025

FY22 $1.34BFY23 $1.09BFY24 $1.15BFY25 $1.14B

Total Debt

+106.3% YoY

$99.0MFY 2025

FY22 —FY23 $0.00FY24 $48.0MFY25 $99.0M

Op. Cash Flow

-183.5% YoY

$-482.0MFY 2025

FY22 $438.0MFY23 $-306.0MFY24 $-170.0MFY25 $-482.0M

Free Cash Flow

-175.0% YoY

$-484.0MFY 2025

FY22 $432.0MFY23 $-330.0MFY24 $-176.0MFY25 $-484.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$247.0M -4.3%	$258.0M +120.5%	$117.0M +4.5%	$112.0M -70.8%	$383.0M +391.0%	$78.0M
Net Income	$-353.0M -24.7%	$-283.0M +7.8%	$-307.0M -15.0%	$-267.0M -603.8%	$53.0M +143.1%	$-123.0M
Operating Income	$-386.0M -17.0%	$-330.0M +2.9%	$-340.0M -21.4%	$-280.0M -618.5%	$54.0M +143.5%	$-124.0M
EPS (Diluted)	$-3.29 -4.8%	$-3.14 +24.3%	$-4.15 -11.9%	$-3.71 -622.5%	$0.71 +131.7%	$-2.24
Total Assets	$1.14B -1.0%	$1.15B +5.0%	$1.09B -18.6%	$1.34B -15.5%	$1.59B +106.1%	$772.3M
Total Debt	$99.0M +106.3%	$48.0M	$0.00	—	—	—
Operating Cash Flow	$-482.0M -183.5%	$-170.0M +44.4%	$-306.0M -169.9%	$438.0M +271.1%	$-256.0M -330.6%	$111.0M
Free Cash Flow	$-484.0M -175.0%	$-176.0M +46.7%	$-330.0M -176.4%	$432.0M +253.2%	$-282.0M -361.1%	$108.0M

Get alerted when RCUS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arcus Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RCUS

GILEAD SCIENCES, INC.
$968.8M31,424,760 sh
BlackRock, Inc.
$506.1M16,416,249 sh
STATE STREET CORP
$185.9M6,029,484 sh
WELLINGTON MANAGEMENT GROUP LLP
$181.8M5,895,448 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$147.3M4,776,423 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$138.0M4,475,528 sh
FMR LLC
$124.9M4,049,757 sh
VANGUARD CAPITAL MANAGEMENT LLC
$119.9M3,888,346 sh
CITADEL ADVISORS LLC
$96.7M3,135,057 sh
Woodline Partners LP
$92.7M3,007,798 sh

Fund	Value	Shares
GILEAD SCIENCES, INC.	$968.8M	31,424,760
BlackRock, Inc.	$506.1M	16,416,249
STATE STREET CORP	$185.9M	6,029,484
WELLINGTON MANAGEMENT GROUP LLP	$181.8M	5,895,448
SUVRETTA CAPITAL MANAGEMENT, LLC	$147.3M	4,776,423
VANGUARD PORTFOLIO MANAGEMENT LLC	$138.0M	4,475,528
FMR LLC	$124.9M	4,049,757
VANGUARD CAPITAL MANAGEMENT LLC	$119.9M	3,888,346
CITADEL ADVISORS LLC	$96.7M	3,135,057
Woodline Partners LP	$92.7M	3,007,798

Companies Similar to RCUS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

DNTH

Dianthus Therapeutics, Inc. /DE/

AI score

Very similar · 20 shared holders

BAKER BROS. ADVISORS LP Logos Global Management LP Candriam S.C.A.

Equillium, Inc.

AI score

Very similar · 6 shared holders

Decheng Capital LLC abrdn plc DIADEMA PARTNERS LP

IDYA

IDEAYA Biosciences, Inc.

AI score

Very similar · 19 shared holders

Sofinnova Ventures Inc BAKER BROS. ADVISORS LP Candriam S.C.A.

CLDX

Celldex Therapeutics, Inc.

AI score

Very similar · 20 shared holders

BAKER BROS. ADVISORS LP Logos Global Management LP Candriam S.C.A.

WVE

Wave Life Sciences, Inc.

AI score

Very similar · 12 shared holders

abrdn plc BAKER BROS. ADVISORS LP Susquehanna Portfolio Strategies, LLC

NRIX

Nurix Therapeutics, Inc.

AI score

Similar quality profile · 13 shared holders

Soleus Capital Management, L.P.BAKER BROS. ADVISORS LP Sofinnova Ventures Inc

ZYME

Zymeworks Inc.

AI score

Similar quality profile · 9 shared holders

DIADEMA PARTNERS LP PLATINUM INVESTMENT MANAGEMENT LTD TEMA ETFS LLC

ACRS

Aclaris Therapeutics, Inc.

AI score

Similar quality profile · 4 shared holders

Decheng Capital LLC Rock Springs Capital Management LP Logos Global Management LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RCUS on your watchlist

Track score changes the day Arcus Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RCUS a good stock to buy?

13F Pro's AI-powered analysis of Arcus Biosciences, Inc. (RCUS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RCUS are available on the RCUS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RCUS is classified as a mid company.

Which hedge funds own RCUS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RCUS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcus Biosciences, Inc.'s investment landscape.